Neuland LaboratoriesNSE:NEULANDLAB -0.23%90 Return-on-Tangible-Equity is 53.54% as of Mar. 2026, which is 192% above its 10-year median of 18.32. GuruFocus rates NSE:NEULANDLAB with a GF Score™ of 90/100 and a GF Value™ of ₹16,516.85 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 898 Drug Manufacturers companies, Neuland Laboratories ranks better than 84.97% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Neuland Laboratories's annualized net income for the quarter that ended in Mar. 2026 was ₹8,507 Mil. Neuland Laboratories's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹15,887 Mil. Therefore, Neuland Laboratories's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 53.54%.
The historical rank and industry rank for Neuland Laboratories's Return-on-Tangible-Equity or its related term are showing as below:
NSE:NEULANDLAB'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 3.83 Med: 18.32 Max: 35.01
Current: 26.24
During the past 13 years, Neuland Laboratories's highest Return-on-Tangible-Equity was 35.01%. The lowest was 3.83%. And the median was 18.32%.
NSE:NEULANDLAB's Return-on-Tangible-Equity is ranked better than 84.97% of 898
companies
in the Drug Manufacturers industry
Industry Median: 7.88
vs NSE:NEULANDLAB: 26.24
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Neuland Laboratories Return-on-Tangible-Equity Related Terms
Neuland Laboratories Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Neuland Laboratories's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NEULANDLAB vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuland Laboratories Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Neuland Laboratories's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 53.54% mean?
Neuland Laboratories (NSE:NEULANDLAB) has a Return-on-Tangible-Equity of 53.54% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Neuland Laboratories and its competitors. This is 192% above median its historical median of 18.32. Over the past decade, Neuland Laboratories' Return-on-Tangible-Equity has ranged from 3.83 to 35.01. According to the industry distribution chart, Neuland Laboratories ranks #135 out of 898 companies in the Drug Manufacturers industry, placing it in the top 15%.
Is Neuland Laboratories' Return-on-Tangible-Equity too high?
Neuland Laboratories' current Return-on-Tangible-Equity of 53.54% is 192% above median its 10-year median of 18.32. Over the past 10 years, this metric has ranged from a low of 3.83 to a high of 35.01. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.88. Neuland Laboratories' value of 53.54% is 579.4% above this industry median. Based on the distribution chart, Neuland Laboratories ranks #135 out of 898 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Neuland Laboratories has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #135 out of 898 companies for Return-on-Tangible-Equity. This places Neuland Laboratories in the top 15% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.88. Neuland Laboratories' value of 53.54% is 579.4% above this benchmark. Historically, Neuland Laboratories' own Return-on-Tangible-Equity has ranged from 3.83 to 35.01 over the past decade. While the company's 10-year median is 18.32 vs. the industry median of 7.88, Neuland Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.88, based on 898 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuland Laboratories's current Return-on-Tangible-Equity of 53.54% is 579.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Neuland Laboratories and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current Return-on-Tangible-Equity is 53.54%, which is 192% above median its own 10-year median of 18.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹16,516.85, compared to a current price of ₹18,944.00 — trading 14.7% above its estimated fair value. The current Return-on-Tangible-Equity is 53.54%, which is 192% above median its 10-year median of 18.32 and 579.4% above the Drug Manufacturers industry median of 7.88. Neuland Laboratories' overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current Return-on-Tangible-Equity is 53.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued.
The current stock price of ₹18,944.00 is trading 14.7% above its estimated GF Value™ of ₹16,516.85.
GuruFocus considers Neuland Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:NEULANDLAB:
Return-on-Tangible-Equity: 53.54% (192% above median its 10-year median of 18.32)
GF Value™: ₹16,516.85 vs. price of ₹18,944.00 (14.7% above fair value)
Industry Position: 579.4% above the Drug Manufacturers median (#135 of 898)
No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
90GF Score
Get the complete analysis for NSE:NEULANDLAB
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEULANDLAB has been successfully added to your 
